DATA GRAPHICS | Data Byte
Preclinical IPO companies don’t stay preclinical for long
Preclinical status comes with risk for IPO investors, but most of the companies enter the clinic within a few months
October 17, 2022 11:35 PM UTC
Most biotechs that are preclinical at the time of their IPO are poised to enter clinical trials quickly, finds an analysis by BioCentury.
Despite the extra risk that comes with investing in a company that has not yet entered the clinic, the number of preclinical biotechs that have gone public on NASDAQ has increased in recent years, jumping from two in 2017 to 23 in 2020...